Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pfizer (PFE)
NYSE:PFE
Holding PFE?
Track your performance easily
PFE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.48 - $31.54
Previous CloseN/A
Volume12.20M
Average Volume (3M)39.81M
Market Cap
$149.67B
Enterprise Value$223.98B
Total Cash (Recent Filing)$17.85B
Total Debt (Recent Filing)$30.40B
Price to Earnings (P/E)35.2
Beta0.23
Next Earnings
Feb 04, 2025EPS Estimate
0.47Next Dividend Ex-Date
Jan 24, 2025Dividend Yield6.36%
Share Statistics
EPS (TTM)0.74
Shares Outstanding5,666,990,000
10 Day Avg. Volume33,143,144
30 Day Avg. Volume39,806,558
Standard Deviation0.08
R-Squared0.17
Alpha-0.00639
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.47
Price to Cash Flow (P/CF)5.50
P/FCF Ratio5.50
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue3.73
Enterprise Value/Gross Profit6.68
Enterprise Value/Ebitda14.69
Forecast
1Y Price Target
$31.56Price Target Upside19.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Pfizer News
Bulls Say, Bears Say
Bulls Say
Cash Flow ImprovementFuture Paxlovid deliveries will be recorded as cash, improving PFE's cash flow.
Financial PerformancePfizer's shares are considered undervalued, given potentially better fundamentals relative to U.S. BioPharma peers, with potential top-line growth and margin expansion underappreciated.
Oncology PortfolioPfizer's CEO indicated that radical change from the Trump administration could be beneficial for the company's oncology portfolio, spurring new investment opportunities.
Bears Say
Financial PerformanceRevenues guidance mid-point was below expectations, implying potential challenges in achieving higher revenue growth.
Market CompetitionUpcoming patent expiries and competition create uncertainty for the long-term outlook of Pfizer's larger franchises.
Policy ImpactThe Part D redesign in 2025 will have a net negative impact of approximately $1B on revenue.
---
Ownership Overview
0.03% Insiders
18.30% Mutual Funds
0.45% Other Institutional Investors
60.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PFE FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest stock price was $24.48 and its highest was $31.54 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is $149.67B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is Feb 04, 2025 which is in 17 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Oct 29, 2024. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.614 by $0.446.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer pays a Quarterly dividend of $1.676 which represents an annual dividend yield of 6.36%. See more information on Pfizer dividends here
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.47.
How many shares outstanding does Pfizer have?
Pfizer has 5,666,990,000 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $1.06 in its last earnings report, beating expectations of $0.614. Following the earnings report the stock price went down -1.407%.
Which hedge fund is a major shareholder of Pfizer?
Among the largest hedge funds holding Pfizer’s share is Diamond Hill Capital Management Inc. It holds Pfizer’s shares valued at 479M.
---
Pfizer Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.56 (19.14% Upside)
$31.56 (19.14% Upside)
Blogger Sentiment
Bullish
PFE Sentiment 92%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.74%
12-Months-Change
Fundamentals
Return on Equity
4.62%
Trailing 12-Months
Asset Growth
2.07%
Trailing 12-Months
Company Description
Pfizer
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
---
PFE Company Deck
---
PFE Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Pfizer delivered strong Q3 2024 performance with significant revenue growth, driven by oncology and COVID-19 products. The company increased its full-year guidance and continued to make strategic advancements in its pipeline. However, challenges include the withdrawal of Oxbryta and uncertainties related to the Inflation Reduction Act.Read More>---
PFE Revenue Breakdown
52.29% Primary Care
25.59% Specialty Care
19.88% Oncology
2.24% BUSINESS INNOVATION
---
PFE Stock 12 Month Forecast
Average Price Target
$31.56
▲(19.14% Upside)
Technical Analysis
Merck & Company
―
Johnson & Johnson
―
Bristol-Myers Squibb
―
AbbVie
―
GlaxoSmithKline
―
Novartis
―
Best Analysts Covering PFE
1 Year
1 Year Success Rate
27/35 ratings generated profit
1 Year Average Return
+5.55%
reiterated a buy rating last month
Copying Vamil Divan's trades and holding each position for 1 Year would result in 77.14% of your transactions generating a profit, with an average return of +5.55% per trade.
---